ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-PD-L1/Anti-Vd1 T-cell Engager TAK-505

Its studies are led by Takeda.

Furthest: phase 2, since Feb 5, 20261 company-led study, 1 open or runningNext primary completion: Aug 18, 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Takeda11 open or runningphase 2since Feb 5, 2026Feb 5, 2026Aug 18, 2030phase 2 · NCT07436728

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 5, 2026First study: phase 2 study in Malignant Solid TumorsFirst studyNCT07436728 · 151 planned · United States

Ahead

  1. Aug 18, 2030Primary completion: phase 2 study in Malignant Solid TumorsNCT07436728

TargetBeta

CD274 →TRDV1 →read by rule
“A bispecific antibody and T-cell engager (TCE) targeting the immune checkpoint protein human programmed death-ligand 1 (PD-L1; cluster of differentiation 274; CD274) and the variable delta 1 (Vd1; Vdelta1; TRDV1) segment of the gamma-delta (gd) T-cell receptor (TCR) on gdT-lymphocytes, ”NCIt, by rule

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07436728Malignant Solid Tumors · United States2RecruitingAug 18, 2030151

How it is read

Names in the registry

  • “TAK-505”, 1 entry

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.